Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes

Kyle R Gibson; Tim J Winterburn; Fiona Barrett; Sushma Sharma; Sandra M MacRury; Ian L Megson

doi:10.1186/1475-2840-10-43

Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes

Kyle R Gibson
, Tim J Winterburn
, Fiona Barrett
, Sushma Sharma
, Sandra M MacRury
, Ian L Megson

Publikation: Article › Begutachtung

58 Zitate (Scopus)

Abstract

Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.

Originalsprache	English
Seiten (von - bis)	43
Fachzeitschrift	Cardiovascular Diabetology
Jahrgang	10
DOIs	https://doi.org/10.1186/1475-2840-10-43
Publikationsstatus	Published - 2011

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Good health and well being

Zugriff auf Dokument

10.1186/1475-2840-10-43

Dieses zitieren

@article{fd37377ca1dc4d77ab937c94ef646ca0,

title = "Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes",

abstract = "Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.",

author = "Gibson, \{Kyle R\} and Winterburn, \{Tim J\} and Fiona Barrett and Sushma Sharma and MacRury, \{Sandra M\} and Megson, \{Ian L\}",

year = "2011",

doi = "10.1186/1475-2840-10-43",

language = "English",

volume = "10",

pages = "43",

journal = "Cardiovascular Diabetology",

issn = "1475-2840",

publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes

AU - Gibson, Kyle R

AU - Winterburn, Tim J

AU - Barrett, Fiona

AU - Sharma, Sushma

AU - MacRury, Sandra M

AU - Megson, Ian L

PY - 2011

Y1 - 2011

N2 - Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.

AB - Platelet hyperaggregability is a pro-thrombotic feature of type-2 diabetes, associated with low levels of the antioxidant glutathione (GSH). Clinical delivery of N-acetylcysteine (NAC), a biosynthetic precursor of GSH, may help redress a GSH shortfall in platelets, thereby reducing thrombotic risk in type-2 diabetes patients. We investigated the effect of NAC in vitro, at concentrations attainable with tolerable oral dosing, on platelet GSH concentrations and aggregation propensity in blood from patients with type-2 diabetes.

U2 - 10.1186/1475-2840-10-43

DO - 10.1186/1475-2840-10-43

M3 - Article

C2 - 21600014

SN - 1475-2840

VL - 10

SP - 43

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

ER -

Therapeutic potential of N-acetylcysteine as an antiplatelet agent in patients with type-2 diabetes

Abstract

UN SDGs

Zugriff auf Dokument

Fingerprint

Dieses zitieren